The responses of DLD-1 and HCT-15 human colon adenocarcinoma cells to hyperthermia, 5-fluorouracil (5-FU)/leucovorin, carboplatin and tumor necrosis factor-alpha, singly and in multiple combinations, were evaluated in clonogenic assays. The combination of hyperthermia with the lower dose combination resulted in a survival fraction of about 0.005 to 0.001 for both cell types, whereas estimated additive interactions alone would have resulted in a survival fraction of about 0.5 (DLD-1) or 0.05 (HCT-15). A survival fraction of 0.00001 or greater was observed when the higher dose levels were combined with hyperthermia, whereas additive interactions alone would have achieved a decrease of only 0.001 or 0.0001 in the surviving fraction. The combination of the three other modalities at either dose level under conditions of hyperthermia or normothermia achieved statistically significant apparently supra-additive losses of clonogenicity in HCT-15 cells; similar results were obtained with the lower dose level in DLD-1 cells. Our results suggest that human colon tumor cells are markedly sensitive to this combination of modalities when used at clinically achievable dose levels.
Skip Nav Destination
Close
Article navigation
January 1995
Research Article|
January 01 1995
Clonogenic Survival Studies of Human Colon Tumor Cell Lines In Vitro: Combined Hyperthermia, 5-Fluorouracil/Leucovorin, Carboplatin and Tumor Necrosis Factor
Radiat Res (1995) 141 (1): 44–48.
Citation
Jim Klostergaard, M. Elena Leroux, Stephen P. Tomasovic; Clonogenic Survival Studies of Human Colon Tumor Cell Lines In Vitro: Combined Hyperthermia, 5-Fluorouracil/Leucovorin, Carboplatin and Tumor Necrosis Factor. Radiat Res 1 January 1995; 141 (1): 44–48. doi: https://doi.org/10.2307/3579088
Download citation file:
Close
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Commonalities Between COVID-19 and Radiation Injury
Carmen I. Rios, David R. Cassatt, Brynn A. Hollingsworth, Merriline M. Satyamitra, Yeabsera S. Tadesse, Lanyn P. Taliaferro, Thomas A. Winters, Andrea L. DiCarlo
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
Pataje G. Prasanna, Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, Silvia C. Formenti, Chandan Guha, Dale J. Hu, Mohammad K. Khan, David G. Kirsch, Sunil Krishnan, Wolfgang W. Leitner, Brian Marples, William McBride, Minesh P. Mehta, Shahin Rafii, Elad Sharon, Julie M. Sullivan, Ralph R. Weichselbaum, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Kathryn D. Held
Germicidal Efficacy and Mammalian Skin Safety of 222-nm UV Light
Manuela Buonanno, Brian Ponnaiya, David Welch, Milda Stanislauskas, Gerhard Randers-Pehrson, Lubomir Smilenov, Franklin D. Lowy, David M. Owens, David J. Brenner